Hiroyuki Murai

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 668 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +4

Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis

Takaaki Ishizu, Manabu Osoegawa, Feng-Jun Mei et al. · Brain · 2005 · 334 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Intracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease

Yasumasa Ohyagi, Hideaki Asahara, De-Hua Chui et al. · The FASEB Journal · 2004 · 279 citations

Life Sciences, Molecular Biology, Neuroscience +17

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

James F. Howard, Saskia Bresch, Angela Genge et al. · The Lancet Neurology · 2023 · 250 citations

Medicine, Pharmacotherapy, Pain Management +2